 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 855554
Online Users : 1205
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13507
|
| Title: | Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes |
| Authors: | Yen, FS;Wei, CC;Liu, JS;Hsu, CC;Hwu, CM |
| Contributors: | Institute of Population Health Sciences |
| Abstract: | AIM: People with young-onset diabetes (YOD) exhibit a higher risk of morbidity and mortality than those with late-onset diabetes. Few studies have explored the preferred management of diabetes in such patients. We compared the risks of hospitalization and mortality among people with YOD to whom second-line oral antidiabetic drugs (OADs) were administered. METHODS: 7257 people taking second-line OADs after initial metformin therapy were enrolled during 2009-2014. Using add-on sulfonylureas (SUs) as a reference, the multivariable Cox regression model was used to compare the hospitalization and mortality risks among 5 categories of second-line OADs: alpha-glucosidase inhibitors, meglitinide, dipeptidyl peptidase-4 (DPP-4) inhibitors, SUs, and thiazolidinediones. RESULTS: After baseline characteristics, comorbidities, duration of diabetes, and drug use were controlled, the adjusted hazard ratios and 95% confidence interval for all-cause, cardiovascular, and non-infection hospitalization and all-cause mortality for metformin plus DPP-4 inhibitors were 0.62 (0.52-0.73), 0.49 (0.29-0.85), 0.64 (0.54-0.76), and 0.50 (0.27-0.92), respectively, when compared with the data for metformin plus SUs. CONCLUSIONS: Among people with YOD, taking add-on DPP-4 inhibitors was associated with lower risks of all-cause hospitalization and mortality than taking add-on SUs. DPP-4 inhibitors thus seem to be a suitable second-line OAD for such patients. |
| Date: | 2021-07 |
| Relation: | Diabetes Research and Clinical Practice. 2021 Jul;177:Article number 108928. |
| Link to: | http://dx.doi.org/10.1016/j.diabres.2021.108928 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8227&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000680513200006 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85109531337 |
| Appears in Collections: | [許志成] 期刊論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| PUB34171441.pdf | 807Kb | Adobe PDF | 196 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
